Highlights the clinical implications of clopidogrel resistance and variability in response due to genetic and individual factors in patients with acute coronary syndrome.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to clopidogrel variability in ACS; leaves open personalized strategies pending prospective trials.
Despite its recognized efficacy in the treatment of acute coronary artery disease and of patients undergoing interventional cardiology procedures, clopidogrel is far from a perfect drug.It is a thienopyridine, and its antiplatelet effect is due to irreversible inhibition of P2Y12 receptors, blocking their reactivity to ADP stimulation.Since it is a prodrug that requires two metabolic processes in the liver to produce its active form, patients present considerable variation in response and hence in levels of platelet inhibition.A high proportion do not attain adequate levels, resulting in therapeutic inefficacy; this situation has been given various names ---resistance, variability, unresponsiveness ---to express the idea that not all patients receive the same therapeutic benefit, which is why thrombotic phenomena can occur even in patients under antiplatelet therapy, suggesting a failure of the therapy itself.The effect of antiplatelet drugs is influenced by multiple factors, many of them inherent to the individual patient, including a genetic component, as several polymorphisms are known to be associated with loss of drug function.Curiously, the medical community has been far more concerned with loss of function and consequent residual ଝ Please cite this article as:
No takes yet. Share an insight, caveat, or question.
João Morais (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: